A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status:
Recruiting
Trial end date:
2024-06-24
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, maximum tolerated doses
(MTDs) and recommended Phase 2 doses (RP2Ds) of JNJ-74856665 as monotherapy and/or in
combinations.